Data published in the circulating ...

Data published in the circulating issue of Menopause show that after five years of treatment with Evista (Ell Lilly and Company, Indianapolis, IN, raloxifene HCl) the unsalable article preserved bone mineral density (BMD) significantly reduc the likelihood of developing osteoporosis, and was not associated with endometrial stimulation or cancer in healthy postmenopausal women The data were derived from sum of two units double-blind, randomized, placebo-controlled trials that were designed as three-year studies with a two-year extension phase. The passing from hand to hand study followed 328 women (average age of 55 years